NATRIURETIC PEPTIDE: DIAGNOSTIC, PROGNOSTIC, AND CLINICAL RELEVANCE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, ARTERIAL HYPERTENSION AND OBESITY
DOI:
https://doi.org/10.21856/j-PEP.2024.1.01Keywords:
natriuretic peptide, type 2 diabetes, arterial hypertension, obesityAbstract
Natriuretic peptides are one of the main biomarkers of chronic heart failure (CHF). The level of NT-proBNP makes it possible to evaluate the negative prognosis in patients with CHF, as well as to monitor the sensitivity of patients with left ventricular dysfunction to the appointment of treatment. The purpose of the study: to study the NT-proBNP biomarker in comorbid patients with hypertension, obesity, type 2 diabetes and determine the relationship with a number of hormonal and biochemical indicators.
Materials and methods: all patients were divided into 4 groups depending on the presence of comorbid pathology in them: patients with hypertension – 1 group – 22 people; patients with hypertension combined with obesity – group 2 – 30 people; Hypertension in combination with type 2 diabetes – group 3 – 31 people; patients with hypertension, type 2 diabetes and obesity – group 4 – 28 people. Determination of the content of N-terminal brain natriuretic peptide (NT-proBNP) in the blood serum of patients was carried out by the immunoenzymatic method on the analyzer "Labline-90" (Austria) using a commercial test system manufactured by the company "Elabscience" (ELISA, China) according to the instructions, which was part of the set.
Conclusions. It was established that in patients with hypertension, hypertension in combination with obesity, hypertension in combination with type 2 diabetes, as well as hypertension in combination with type 2 diabetes and obesity, there is a significant increase in NT-proBNP compared to the indicator of the control group (p<0.05). It has been proven that NT-proBNP has a direct correlation with creatinine (p=0.045), urea (p=0.038), triglyceride level (p=0.027) and cholesterol (p=0.031); direct correlation with the level of HbA1c (r=0.202; p=0.0038). The level of NT-proBNP has a significant predictive value for the risk of developing cardiovascular complications in patients with hypertension.
References
Cao Z, Jia Y, Zhu B. Int J Mol Sci 2019;20(8): 1820. http://doi.org/10.3390/ijms20081820.
Madamanchi C, Alhosaini H, Sumida A, Runge MS. Int J Cardiol 2014;176(3): 611-617. http://doi.org/10.1016/j.ijcard.2014.08.007.
Di Stasio E, Russo A, Mettimano M, et al. Clin Chim Acta 2011;412(11-12): 1106-1111. http://doi.org/10.1016/j.cca.2011.02.035.
Oremek GM, Passek K, Holzgreve F, et al. Zentralbl Arbeitsmed Arbeitsschutz Ergon 2023;73(2): 89-95. http://doi.org/10.1007/s40664-022-00491-9.
Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Clin Chim Acta 2004;341(1-2): 41-48. http://doi.org/10.1016/j.cccn.2003.10.027.
Troughton RW, Lewis LK, Yandle TG, et al. Ann Med 2011;43(3): 188-197. http://doi.org/10.3109/07853890.2010.526630.
Richards AM, Nicholls MG, Yandle TG, et al. Circulation 1998;97(19): 1921-1929. http://doi.org/10.1161/01.cir.97.19.1921.
Struthers AD. Eur Heart J 1999;20(19): 1374-1375. http://doi.org/10.1053/euhj.1999.1771.
McDonagh TA, Robb SD, Murdoch DR, et al. Lancet 1998;351(9095): 9-13. http://doi.org/10.1016/s0140-6736(97)03034-1.
Murakami T, Shiraishi M, Murakami T. J Hypertens 2020;38(5): 975. http://doi.org/10.1097/HJH.0000000000002401.
Courand PY, Grandjean A, Harbaoui B, Lantelme P. J Hypertens 2020;38(5): 976. http://doi.org/10.1097/HJH.0000000000002402.
Daya NR, McEvoy JW, Christenson RH, et al. Am J Hypertens 2023;36(11): 602-611. http://doi.org/10.1093/ajh/hpad065.
Lapi F, Marconi E, Medea G, et al. Endocrine 2023;82(1): 42-46. http://doi.org/10.1007/s12020-023-03419-2.
Hollstein T, Schlicht K, Krause L, et al. Sci Rep 2021;11(1): 10096 http://doi.org/10.1038/s41598-021-89426-7.
Bayes-Genis A. Diabetes Res Clin Pract 2022;194: 110165. http://doi.org/10.1016/j.diabres.2022.110165.
Malachias MVB, Wijkman MO, Bertoluci MC. Diabetol Metab Syndr 2022;14(1): 64. http://doi.org/10.1186/s13098-022-00837-6.
Malachias MVB, Jhund PS, Claggett BL, et al. J Am Heart Assoc 2020;9(19): e017462. http://doi.org/10.1161/JAHA.120.017462.
Prausmüller S, Resl M, Arfsten H, et al. Cardiovasc Diabetol 2021;20(1): 34. http://doi.org/10.1186/s12933-021-01221-w.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Problems of Endocrine Pathology
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
